GLP-1s Show Promise in Treating Alcohol and Drug Addiction
Mounjaro (Tirzepatide) A new class of GLP-1 medication that provides dual benefits for both diabetes and weight loss is of particular importance in people who do not necessarily have diabetes
But we often hear from individuals and clinicians alike that Yeah, sure it may work, but its too hard to sustain or its too expensive or my medical practice cant support someone through this transition. Well, this publication demonstrates that none of those claims need to be true
Key findings at the highest dose (12mg weekly): Up to 24% mean body weight reduction over 48 weeks Significant reductions in fasting glucose and insulin resistance markers Meaningful reductions in liver fat content, relevant for participants with metabolic-associated fatty liver disease Once-weekly subcutaneous dosing was generally well-tolerated For context, semaglutide at its approved dose achieves approximately 1517% body weight reduction over 68 weeks
It is even more significant in Mounjaro (tirzepatide) which will likely be FDA approved by the end of the year for weight loss
Appetite remains suppressed, but without the accompanying gastrointestinal distress that made eating difficult during month 2
